新能源助推绿色转型 中国港能打造智慧能源新蓝图
香港, 2024年8月14日 – (亚太商讯 via SeaPRwire.com) – 中国港能智慧能源集团有限公司（股份代号：0931.HK，以下简称“中国港能”）在香港成功召开2024年度业绩投资者交流会。本次活动是自中国港能战略转型后首次面向全球投资者举办的线下交流会，不仅是中国港能在全球能源版图中迈…
Kincora and AngloGold Ashanti’s First Drilling Program
The first ever copper-gold focused drilling program at the northern portion of the Nyngan Project will shortly commence with earn-in partner AngloGold Ashanti Australia (AngloGold Ashanti). New district-scale potential with up to […]
Experience Eternal Romance with Exquisite Blue Diamonds by ALUXE
SINGAPORE, Aug 14, 2024 – (ACN Newswire via SeaPRwire.com) – ALUXE, cherished for its unwavering commitment to celebrating love and happiness, is delighted to introduce 8 stunning new additions to its exclusive “Lovers” […]
Nissin Foods Becomes a Constituent of MSCI Global Micro Cap Index (MSCI Hong Kong Index)
HONG KONG, Aug 14, 2024 – (ACN Newswire via SeaPRwire.com) – Nissin Foods Company Limited (“Nissin Foods” or the “Company”, together with its subsidiaries, the “Group”; Stock code: 1475) is pleased to […]
日清食品为MSCI全球微型股指数（MSCI香港指数）成份股之一
香港, 2024年8月14日 – (亚太商讯 via SeaPRwire.com) – 日清食品有限公司（「日清食品」或「公司」，连同其附属公司统称「集团」；股份代号：1475）欣然宣布集团已获纳入MSCI全球微型股指数（MSCI香港微型股指数），将于2024年8月30日（星期五）生效。 日清食品执行董事、…
Modern DevOps Melbourne 2024 Partners with ACN Newswire; Offers Exclusive Discount
MELBOURNE, Aug 14, 2024 – (ACN Newswire via SeaPRwire.com) – Mark your calendars for an unmissable event! We are thrilled to announce our partnership with the upcoming Modern DevOps Melbourne, taking place […]
Experience Eternal Romance with Exquisite Blue Diamonds
SINGAPORE, Aug 14, 2024 – (ACN Newswire via SeaPRwire.com) – ALUXE, cherished for its unwavering commitment to celebrating love and happiness, is delighted to introduce 8 stunning new additions to its exclusive “Lovers” […]
Sino Biopharmaceutical (1177.HK) Announces 2024 Interim Results
Development Highlights – During the reporting Period, four of the Group’s innovative products were approved for marketing by the National Medical Products Administration of China (“NMPA”), namely Andewei (Benmelstobart Injection), Anboni (Unecritinib […]
中国生物制药（1177.HK）公布2024中期业绩
重点成果 – 期内，集团共有4个创新产品获中国国家药品监督管理局（「NMPA」）批准上市，分别为安得卫（贝莫苏拜单抗注射液）、安柏尼（富马酸安奈克替尼胶囊）、安洛晴（枸橼酸依奉阿克胶囊）和贝乐林（利拉鲁肽注射液），其中3个为国家1类创新药。 – 2024年上半年，集团创新产品收入达到61.3亿元…